Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2019-08-14 Interim / Quarterly Rep…
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2019
2019-08-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2019, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not filed for purposes of certain securities laws, indicating this is a current report announcing earnings results rather than the earnings release itself. The document length is 3665 characters, which is relatively short and consistent with an 8-K filing announcing earnings results. According to the classification rules, an 8-K filing announcing financial results corresponds to an Earnings Release (ER) category, as it is the initial announcement of quarterly financial results with key highlights. Therefore, the appropriate classification is ER with high confidence.
2019-08-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-01 English
SC 13D
Major Shareholding Notification
2019-06-29 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-28 English
OWNERSHIP DOCUMENT
Director's Dealing
2019-06-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.